The fragility index and reverse fragility index of FDA investigational device exemption trials in spinal fusion surgery: a systematic review

Joshua D. Proal,Andrew S. Moon,Brian Kwon
DOI: https://doi.org/10.1007/s00586-024-08317-3
IF: 2.721
2024-05-29
European Spine Journal
Abstract:FDA investigational device exemption (IDE) studies are considered a gold standard of assessing safety and efficacy of novel devices through RCTs. The fragility index (FI) has emerged as a means to assess robustness of statistically significant study results and inversely, the reverse fragility index (RFI) for non-significant differences. Previous authors have defined results as fragile if loss to follow up is greater than the FI or RFI. The aim of this study was to assess the FI, RFI, and robustness of data supplied by IDE studies in spinal surgery.
clinical neurology,orthopedics
What problem does this paper attempt to address?